Loading
Latest filing published 14 Jun 2021 for PROGENITY, INC., €16.5M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Athyrium Opportunities Fund (A) LP discloses dealings in Biora Therapeutics, Inc. to SEC (Form 4). Between 1 June 2021 and 14 June 2021, the trades on record add up to 2 filings.
Every open-market trade on record is a purchase: 2 purchases worth €17.2M, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
Most recently, on 14 June 2021, the filings show an open-market purchase worth €16.5M in Biora Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations